Snellen Holdings

Snellen Holdings is a biotechnology company focused on the development of innovative therapies for ophthalmological disorders, particularly inherited retinal diseases. The company leverages advanced research in gene therapy and molecular biology to target conditions such as retinitis pigmentosa and Stargardt disease. By focusing on specific genetic targets like rhodopsin, Snellen Holdings aims to provide disease-modifying treatments that can preserve or restore vision in patients with limited options. The company operates primarily in the pre-clinical stage, advancing its pipeline through rigorous scientific validation and strategic collaborations within the life sciences ecosystem.